You are here: Industry Insights > mRNA

News List

Phase I trial of mRNA-based influenza vaccine begins europeanpharmaceuticalreview
June 24, 2021
The trial will assess a monovalent mRNA-based vaccine candidate against seasonal influenza caused by the A/H3N2 strain.
mRNA-based therapeutic cancer vaccine enters Phase II trial europeanpharmaceuticalreview
June 24, 2021
BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111, in combination with Libtayo? (cemiplimab) for the treatment of melanoma.
Study Suggests COVID Vaccine Booster Shots Will Be Needed drugs
June 24, 2021
One dose of a two-dose mRNA COVID-19 vaccine is enough to protect previously infected people, but it's likely they and everyone with two doses will still require booster shots at a later date, a new study suggests.
Sanofi and Translate Bio start clinical trial for mRNA flu vaccine expresspharma
June 23, 2021
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Collaboration to develop novel polymer-based drug delivery system for mRNA europeanpharmaceuticalreview
June 22, 2021
Evonik and Stanford University will collaborate over three years to advance an innovative polymer-based drug delivery system that could further the use of mRNA therapeutics.
CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV worldpharmanews
June 21, 2021
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced results of the second interim analysis of its international pivotal Phase 2b/3 study in ...
Australia's first locally made COVID-19 mRNA vaccine candidate is set for clinical trials firstwordpharma
June 21, 2021
Victoria's acting premier James Merlino announced on Sunday his government had allocated AUD 5 million from a AUD 50 million mRNA research fund to help the Monash Institute of Pharmaceutical Sciences manufacture doses of its mRNA vaccine candidate for tri
Danaher to acquire Aldevron from EQT for $9.6bn pharmaceutical-business-review
June 18, 2021
Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.
U.S. government purchases additional 200 million doses of Moderna's COVID-19 vaccine worldpharmanews
June 17, 2021
Moderna announced that the U.S. government has purchased an additional 200 million doses of Moderna's COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna's pipeline.
China’s First mRNA Covid-19 Vaccine Preps to Enter Final Stage Trials, Abogen CEO Says firstwordpharma
June 17, 2021
Suzhou Abogen Biosciences’ mRNA COVID-19 vaccine? is expected to start Phase III tests in overseas countries later this month, said CEO Ying Bo, Yicai Global reported.